Skip to main content
Journal cover image

Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries.

Publication ,  Journal Article
Chau, KH; Douglas, PS; Pibarot, P; Hahn, RT; Khalique, OK; Jaber, WA; Cremer, P; Weissman, NJ; Asch, FM; Zhang, Y; Gertz, ZM; Elmariah, S ...
Published in: J Am Coll Cardiol
May 19, 2020

BACKGROUND: Greater early left ventricular mass index (LVMi) regression is associated with fewer hospitalizations 1 year after transcatheter aortic valve replacement (TAVR). The association between LVMi regression and longer-term post-TAVR outcomes is unclear. OBJECTIVES: The purpose of this study was to determine the association between LVMi regression at 1-year post-TAVR and clinical outcomes between 1 and 5 years. METHODS: Among intermediate- and high-risk patients who received TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) I, II, and S3 trials or registries and were alive at 1 year, we included patients with baseline moderate or severe left ventricular hypertrophy (LVH) and paired measurements of LVMi at baseline and 1 year. The associations between LVMi regression (percent change between baseline and 1 year) and death or rehospitalization from 1 to 5 years were examined. RESULTS: Among 1,434 patients, LVMi was 146 g/m2 (interquartile range [IQR]: 133 to 168 g/m2) at baseline and decreased 14.5% (IQR: 4.2% to 26.1%) to 126 g/m2 (IQR: 106 to 148 g/m2) at 1 year. After adjustment, greater LVMi regression at 1 year was associated with lower all-cause death (adjusted hazard ratio [aHR]: 0.95 per 10% decrease in LVMi; 95% confidence interval [CI]: 0.91 to 0.98; p = 0.004; aHR of the quartile with greatest vs. least LVMi regression: 0.61; 95% CI: 0.43 to 0.86; p = 0.005). Severe LVH at 1 year was observed in 39%, which was independently associated with increased all-cause death (aHR of severe LVH vs. no LVH: 1.71; 95% CI: 1.20 to 2.44; p = 0.003). Similar associations were found for rates of cardiovascular mortality and rehospitalization. CONCLUSIONS: Among patients with moderate or severe LVH treated with TAVR who are alive at 1 year, greater LVMi regression at 1 year is associated with lower death and hospitalization rates to 5 years. These findings may have implications for the timing of valve replacement and the role of adjunctive medical therapy after TAVR.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

May 19, 2020

Volume

75

Issue

19

Start / End Page

2446 / 2458

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transcatheter Aortic Valve Replacement
  • Registries
  • Mortality
  • Male
  • Hypertrophy, Left Ventricular
  • Humans
  • Female
  • Cardiovascular System & Hematology
  • Aortic Valve Stenosis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chau, K. H., Douglas, P. S., Pibarot, P., Hahn, R. T., Khalique, O. K., Jaber, W. A., … Lindman, B. R. (2020). Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Coll Cardiol, 75(19), 2446–2458. https://doi.org/10.1016/j.jacc.2020.03.042
Chau, Katherine H., Pamela S. Douglas, Philippe Pibarot, Rebecca T. Hahn, Omar K. Khalique, Wael A. Jaber, Paul Cremer, et al. “Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries.J Am Coll Cardiol 75, no. 19 (May 19, 2020): 2446–58. https://doi.org/10.1016/j.jacc.2020.03.042.
Chau KH, Douglas PS, Pibarot P, Hahn RT, Khalique OK, Jaber WA, et al. Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Coll Cardiol. 2020 May 19;75(19):2446–58.
Chau, Katherine H., et al. “Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries.J Am Coll Cardiol, vol. 75, no. 19, May 2020, pp. 2446–58. Pubmed, doi:10.1016/j.jacc.2020.03.042.
Chau KH, Douglas PS, Pibarot P, Hahn RT, Khalique OK, Jaber WA, Cremer P, Weissman NJ, Asch FM, Zhang Y, Gertz ZM, Elmariah S, Clavel M-A, Thourani VH, Daubert M, Alu MC, Leon MB, Lindman BR. Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. J Am Coll Cardiol. 2020 May 19;75(19):2446–2458.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

May 19, 2020

Volume

75

Issue

19

Start / End Page

2446 / 2458

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Transcatheter Aortic Valve Replacement
  • Registries
  • Mortality
  • Male
  • Hypertrophy, Left Ventricular
  • Humans
  • Female
  • Cardiovascular System & Hematology
  • Aortic Valve Stenosis